SAHPRA Tag

Between 60 and 100 chemicals called cannabinoids and some 300 non-cannabinoid chemicals are produced by the cannabis plant. Delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD) are two of the many cannabinoids present in the cannabis plant, in varying concentrations. THC is psychoactive in nature and is...

In February 2019 the South African Health Products Regulatory Authority (SAHPRA) received reports suggesting fraudulent activity implicating a small sector of the authority and an external stakeholder. SAHPRA’s acting-CEO, the Board and the Health Minister reported the allegations to the Special Investigating Unit (SIU) and...

The South African Health Products Regulatory Authority (SAHPRA) notes with concern the statement made on Cape Talk Radio that the regulatory authority has issued the first commercial licences for the growing and manufacturing of cannabis. The mandate of the regulatory authority is to issue licences...

The South African Health Products Regulatory Authority (SAHPRA) has learned about the safety concerns regarding the presence of a nitrosamine impurity called NDMA in ranitidine-containing medicines. NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on the results of...

SAHPRA is pleased to announce the appointment of a new Chief Executive Officer, Dr Boitumelo Semete-Makokotlela, who will commence with this role in January 2020. Dr Semete-Makokotlela holds a Ph.D. in Biochemistry (North-West University) and an MSc in Management Finance and Investment from Wits Business...

The South African Health Products Regulatory Authority (SAHPRA) is updating certain active pharmaceutical ingredient (API) names used in South Africa to bring them into line with international nomenclature. Further name changes are also taking place – to improve consistency within South African approved terminology and...

10 May 2019 SAHPRA is the South African Health Products Regulatory Authority. It is a Section 3A public entity that was formed by the South African government to oversee the regulation of health products which includes medicines, medical devices, in-vitro diagnostic tests and devices, radiation emitting...

The Medicines Control Council wishes to inform prescribers of increased risks of cerebrovascular adverse events (including strokes and transient ischaemic attacks) and mortality associated with the use of atypical antipsychotics in elderly patients with dementia. The atypical antipsychotics to which this medicine safety alert refers...